在蛋白质调节和药物开发中应用蛋白质溶解向化学 (PROTAC) 技术
Yiting He1, Tianzuo Liao2, Xuan'er Wang3
1China Medical University-Queen's University of Belfast Joint College, China Medical University, Shenyang 110122, China; School of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK.
Bioorganic chemistry
|August 12, 2025
概括
与传统药物不同,蛋白质分解向金马 (PROTACs) 提供了一种新的方法,以催化方式降解引起疾病的蛋白质. 这篇评论探讨了它们的进展,治疗各种疾病的潜力,以及诸如分娩和毒性等挑战.
科学领域:
- 生物化学和分子生物学
- 药理学 药理学是指药理学的学科.
- 药物发现 药物发现 药物发现
背景情况:
- 蛋白质分解向化马体 (PROTACs) 在向蛋白质降解方面取得了重大进展.
- 它们利用细胞的泛素-蛋白酶体系统进行选择性蛋白质清除.
- PROTACs提供了一个催化,事件驱动的机制,与需要持续目标占用的传统疗法不同.
研究的目的:
- 审查和分析到2024年的基于PROTAC的药物的开发进展.
- 为了比较PROTACs与传统的治疗方式,如小分子抑制剂和单克隆抗体.
- 突出PROTACs在解决"不可抗药"目标和提高治疗效率方面的潜力.
主要方法:
- 对PROTACs与小分子抑制剂和单克隆抗体进行比较分析.
- 对六个主要疾病领域的PROTAC发展的审查:瘤学,自身免疫,心血管,神经退行性,病毒感染和罕见遗传疾病.
- 探索先进的PROTAC技术,包括对刺激有反应的PROTAC和Nano-PROTAC.
主要成果:
- 在低于静态度的度下,PROTACs显示出具有高效降解细胞内蛋白质的潜力.
- 在将PROTAC应用于各种治疗领域方面,已经观察到显著的进展.
- 确定了诸如E3结合酶限制,全身毒性和输送效率低下等挑战.
结论:
- 先进的PROTAC配方,如刺激反应和Nano-PROTAC,在提高输送精度,组织特异性和降低毒性方面表现有前途.
- 预计PROTACs的未来进展将扩大可药物标的范围,并优化药理动力学.
- PROTAC技术有可能实现更安全,更有效的临床疗法.
相关概念视频
02:58Regulated Protein Degradation
2.6K
2.6K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.8K
02:18The Proteasome
9.1K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
9.1K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:09Recombinant DNA
96.7K
Overview
96.7K